top of page
Heading 2
Displacing opioids with non-addictive pain therapeutics through a new class of analgesics
Healing without dependency to enhance quality of life
Our discovery platform generates new chemical entities (NCEs) that have not been previously explored, potentially offering unique therapeutic opportunities. Utilizing cannabinoid scaffolds, which have known analgesic efficacy, we are developing pain therapeutics that offer a safer option to opioids. The goal is to develop non-addictive painkillers that are as effective as opioids with fewer side effects, including:
✔ No abuse potential
✔ No tolerance
✔ No respiratory depression
✔ No nausea, vomiting, constipation
✔ No drowsiness, dizziness
✔ No gastrointestinal toxicity
Our proprietary drug discovery platform utilizes
generative AI + emerging science to pinpoint the human ECS, naturally balancing the body. By designing, modeling, and screening de novo compounds, our platform allows us to demonstrate therapeutic potential and refine
NCEs to accelerate drug discovery.
A call for change in pain treatment
While pain relief is paramount for the 2.5 billion people who suffer from chronic pain, the addictive nature and widespread misuse of opioids has large economic and societal implications, creating a critical opportunity for innovation.
The opioid problem
1 in 4 patients prescribed opioids for chronic pain misuse them with 10% developing a use disorder. With 143 million opioid prescriptions written annually, opioid overdoses have taken more lives than the wars in Vietnam, Iraq, and Afghanistan combined.
The opioid crisis costs $78.5 billion annually. At Nalu Bio, we see this societal challenge as an urgent need for advanced, non-addictive pain management solutions. Through cutting-edge research and technology, we aim to provide safe, effective alternatives to traditional opioids.
bottom of page